EE200000117A - Asendatud oksindooli derivaadid kui proteiini türosiini kinaasi ja proteiini seriini/treoniini kinaasi inhibiitorid - Google Patents

Asendatud oksindooli derivaadid kui proteiini türosiini kinaasi ja proteiini seriini/treoniini kinaasi inhibiitorid

Info

Publication number
EE200000117A
EE200000117A EEP200000117A EEP200000117A EE200000117A EE 200000117 A EE200000117 A EE 200000117A EE P200000117 A EEP200000117 A EE P200000117A EE P200000117 A EEP200000117 A EE P200000117A EE 200000117 A EE200000117 A EE 200000117A
Authority
EE
Estonia
Prior art keywords
protein
inhibitors
kinase
oxindole derivatives
tyrosine kinase
Prior art date
Application number
EEP200000117A
Other languages
English (en)
Estonian (et)
Inventor
Thomas Davis Stephen
Vernon Frye Stephen
Howard Dickerson Scott
Anthony Harris Philip
Robert Neil Hunter, Iii
Frederick Kuyper Lee
Elizabeth Lackey Karen
Joseph Luzzio Michael
Marvin Veal James
Herrick Walker Duncan
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000117A publication Critical patent/EE200000117A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200000117A 1997-09-05 1998-09-03 Asendatud oksindooli derivaadid kui proteiini türosiini kinaasi ja proteiini seriini/treoniini kinaasi inhibiitorid EE200000117A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718913.8A GB9718913D0 (en) 1997-09-05 1997-09-05 Substituted oxindole derivatives
PCT/EP1998/005559 WO1999015500A1 (fr) 1997-09-05 1998-09-03 Derives substitues d'oxindole en tant qu'inhibiteurs de la tyrosine kinase et de la serine/threonine kinase

Publications (1)

Publication Number Publication Date
EE200000117A true EE200000117A (et) 2000-12-15

Family

ID=10818643

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000117A EE200000117A (et) 1997-09-05 1998-09-03 Asendatud oksindooli derivaadid kui proteiini türosiini kinaasi ja proteiini seriini/treoniini kinaasi inhibiitorid

Country Status (23)

Country Link
US (4) US6387919B1 (fr)
EP (1) EP1009738B1 (fr)
JP (1) JP2001517652A (fr)
KR (1) KR20010023695A (fr)
CN (1) CN1278794A (fr)
AR (1) AR015432A1 (fr)
AT (1) ATE267170T1 (fr)
AU (1) AU747506B2 (fr)
BR (1) BR9812048A (fr)
CA (1) CA2302572A1 (fr)
CO (1) CO4960633A1 (fr)
DE (1) DE69824014T2 (fr)
EE (1) EE200000117A (fr)
ES (1) ES2221211T3 (fr)
GB (1) GB9718913D0 (fr)
HU (1) HUP0004490A3 (fr)
MA (1) MA26542A1 (fr)
PE (1) PE107699A1 (fr)
PL (1) PL338991A1 (fr)
TR (1) TR200001174T2 (fr)
TW (1) TW520358B (fr)
WO (1) WO1999015500A1 (fr)
ZA (1) ZA988078B (fr)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407132B1 (en) * 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6319918B1 (en) 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CA2354402A1 (fr) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles comme inhibiteurs de proteine kinase
BR9916223A (pt) 1998-12-17 2001-09-04 Hoffmann La Roche 4-ariloxindóis como inibidores de cinases de proteìna jnk
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
AU770060B2 (en) * 1998-12-17 2004-02-12 F. Hoffmann-La Roche Ag 4,5-azolo-oxindoles
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
US6492398B1 (en) * 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
GB9911053D0 (en) * 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
DE19924401A1 (de) * 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU6998000A (en) 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
DE60032783T2 (de) * 1999-09-24 2007-12-06 Smithkline Beecham Corp. Thrombopoietinmimetika
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
AU2001252562A1 (en) * 2000-04-28 2001-11-12 Toshiharu Suzuki Medicinal compositions for suppressing beta-amyloid production
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
JP2004505983A (ja) 2000-08-09 2004-02-26 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
CA2411924A1 (fr) 2000-08-18 2002-02-28 Agouron Pharmaceuticals, Inc. Hydroxyimino-fluorenes heterocycliques et leur utilisation pour inhiber des proteines kinases
US7071217B2 (en) * 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
AU8664701A (en) * 2000-09-01 2002-03-22 Glaxo Group Ltd Oxindole derivatives
ES2230337T3 (es) * 2000-09-01 2005-05-01 Glaxo Group Limited Derivados de oxindol.
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
DE10054019A1 (de) * 2000-11-01 2002-05-23 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
SE0101230L (sv) * 2001-04-06 2002-10-07 Innoventus Project Ab Ny användning av en tyrosinkinasinhibitor
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US20050090498A1 (en) * 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
WO2003002108A2 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines au traitement de maladies inflammatoires
CA2461182A1 (fr) * 2001-09-20 2003-05-01 Ab Science Utilisation d'inhibiteurs de la tyrosine kinase pour stimuler la pousse des cheveux
JP2005507916A (ja) * 2001-09-20 2005-03-24 アブ サイエンス 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法
AU2002341881B2 (en) * 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
WO2003027109A1 (fr) * 2001-09-27 2003-04-03 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones, inhibiteurs de kinase
WO2003033491A1 (fr) * 2001-10-16 2003-04-24 Nippon Kayaku Kabushiki Kaisha Composition medicinale de prevention ou de soulagement d'effets secondaires chez les patients souffrant de cancer et composition anticancereuse medicinale
CA2464214C (fr) * 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Inhibiteurs de proteines kinases et de proteines phosphatases, methodes d'identification et methodes d'utilisation associees
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JPWO2003051883A1 (ja) * 2001-12-18 2005-04-28 協和醗酵工業株式会社 インドール誘導体
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP2221054A1 (fr) * 2002-04-30 2010-08-25 Alcon, Inc. Inhibiteurs de CDK pour abaisser la pression intraoculaire
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040082615A1 (en) * 2002-08-07 2004-04-29 Michael Konkel 3-Imino-2-indolones for the treatement of depression and/or anxiety
AU2003259689A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation 3-imino-2-indolones for the treatment of depression and/or anxiety
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
DE60311879T2 (de) 2002-12-23 2007-12-20 Astex Therapeutics Ltd., Cambridge Synthese und screening von liganden mit hilfe von röntgenkristallographie
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
WO2005118551A2 (fr) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
CA2583764C (fr) * 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Composes et methodes visant a reguler l'activite de la thrombopoietine
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US20080125432A1 (en) 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
EP1941798B1 (fr) 2004-12-17 2012-05-23 Devgen NV Compositions nematicides
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
WO2006119660A1 (fr) * 2005-05-11 2006-11-16 Givaudan Sa Procede d'encapsulation
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7749530B2 (en) 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
US7692005B2 (en) 2005-07-13 2010-04-06 Allergan, Inc. Kinase inhibitors
WO2007008985A2 (fr) * 2005-07-13 2007-01-18 Allergan, Inc. Inhibiteurs de kinases
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8987474B2 (en) * 2006-04-07 2015-03-24 University Of South Florida Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8036664B2 (en) * 2006-09-22 2011-10-11 Kineto Wireless, Inc. Method and apparatus for determining rove-out
WO2008045627A2 (fr) * 2006-10-06 2008-04-17 Irm Llc Inhibiteurs de la protéine kinase et procédés pour utiliser ceux-ci
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
AU2008214679A1 (en) * 2007-02-13 2008-08-21 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
US20100143440A1 (en) * 2007-04-30 2010-06-10 The Uab Research Foundation Ul97 inhibitors for treatment of proliferative disorders
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
US7863315B2 (en) * 2008-01-15 2011-01-04 Shenzhen Chipscreen Biosciences, Ltd. 2-indolinone derivatives as selective histone deacetylase inhibitors
WO2009103032A1 (fr) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Composés de pyrimidine-2-amine et leur utilisation en tant qu’inhibiteurs des kinases jak
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2116236A1 (fr) 2008-04-21 2009-11-11 Université de Mons-Hainaut Dérivés de bisbenzamidine pour une utilisation en tant qu'antioxydants
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
WO2009135000A2 (fr) * 2008-04-30 2009-11-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition de la protéine tyrosine phosphatase shp2/ptpn11 par nsc-117199 et analogues
WO2009139834A1 (fr) * 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Composés bioactifs pour le traitement du cancer et des maladies neurodégénératives
PL2307002T3 (pl) * 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
WO2010121212A2 (fr) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Inhibiteurs d'échafaudage d'indoline shp-2 et procédé de traitement du cancer
CA2761896A1 (fr) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Inhibiteurs de kinases cycline-dependantes et leurs procedes d'utilisation
CA2763768A1 (fr) 2009-05-29 2010-12-02 Glaxosmithkline Llc Procedes d'administration de composes agonistes de la thrombopoietine
KR101740076B1 (ko) * 2009-07-28 2017-06-08 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
US8652534B2 (en) * 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
PL2493895T3 (pl) * 2009-10-29 2017-10-31 Vectura Ltd Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3
WO2011100528A2 (fr) 2010-02-12 2011-08-18 Emory University Compositions et utilisations de lectines
SG183285A1 (en) 2010-03-02 2012-09-27 Amakem Nv Heterocyclic amides as rock inhibitors
JP2013533239A (ja) 2010-06-25 2013-08-22 ファキュルテ ユニヴェルシテール ノートル−ダム ド ラ ペ 増殖性疾患の治療に有用なβカルボリン誘導体
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
CA3052927C (fr) 2010-08-18 2023-01-03 Scott D. Boden Composes et compositions pour ossification et procedes associes a ceux-ci
WO2012022780A1 (fr) 2010-08-19 2012-02-23 Université Libre de Bruxelles Dérivés d'acide 18β-glycyrrhétinique ayant une activité antitumorale
MX379532B (es) 2010-10-25 2025-03-10 G1 Therapeutics Inc Inhibidores de cdk.
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP2886120B1 (fr) 2010-10-29 2019-06-19 Emory University Derives quinazoline, compositions et utilisations correspondantes
WO2012061428A2 (fr) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides en tant que modulateurs des jak kinases
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012068381A2 (fr) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection des tissus rénaux contre l'ischémie par le biais de l'inhibition des kinases prolifératives cdk4 et cdk6
WO2012075362A2 (fr) 2010-12-03 2012-06-07 Emory University Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations
US8691777B2 (en) 2011-01-27 2014-04-08 Emory University Combination therapy
CA2826773C (fr) 2011-02-24 2019-07-16 Emory University Compositions antagonistes de jab1 pour ossification et procedes associes a celles-ci
EP2678050B1 (fr) 2011-02-24 2020-10-14 Emory University Compositions antagonistes de noggine pour ossification et procédés associés à celles-ci
WO2012135296A2 (fr) 2011-03-31 2012-10-04 Emory University Composés d'imidazolylamide et leurs utilisations
US10226478B2 (en) 2011-04-14 2019-03-12 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
US20140045936A1 (en) 2011-04-21 2014-02-13 Wake Forest University Health Sciences Cyclopropyl derivatives and methods of use
GB201107223D0 (en) 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
JP2014518859A (ja) 2011-05-09 2014-08-07 ユニバーシタット アントウェルペン ウロキナーゼプラスミノーゲン活性化因子に対する活性依存型プローブ
GB201108225D0 (en) 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
GB201113689D0 (en) 2011-08-09 2011-09-21 Amakem Nv Novel PDE4 inhibitors
US9040567B2 (en) 2011-08-19 2015-05-26 Emory University BAX agonist, compositions, and methods related thereto
GB201114854D0 (en) 2011-08-29 2011-10-12 Amakem Nv Novel rock inhibitors
BR112014004545A2 (pt) 2011-08-31 2017-04-04 Amakem Nv inibidores leves de rock
DK2760867T3 (en) 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
MX342177B (es) 2011-09-30 2016-09-20 Ipsen Pharma Sas Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
DE102011119127A1 (de) * 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
PL2810198T3 (pl) 2012-01-30 2024-01-22 Universiteit Gent Związki przeciwinwazyjne
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
WO2013148748A1 (fr) 2012-03-29 2013-10-03 Francis Xavier Tavares Lactames inhibiteurs de kinases
WO2013181135A1 (fr) 2012-05-31 2013-12-05 Emory University Dérivés de quinazoline, compositions et utilisations associées
CN104487429B (zh) 2012-07-27 2017-07-14 爱默蕾大学 杂环黄酮衍生物、组合物及与其相关的方法
WO2014058921A2 (fr) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Inhibiteurs substitués de pyrimidinyl kinase
US9877981B2 (en) 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
EP2914585B1 (fr) 2012-11-05 2018-03-07 Emory University 7,8-dihydroxyflavone et dérivés de flavone 7,8-substituée, compositions et méthodes associées
WO2014072419A1 (fr) 2012-11-08 2014-05-15 Universiteit Antwerpen Nouveaux composés anti-vih
SI2951172T1 (sl) 2013-01-29 2017-08-31 Redx Pharma Plc Piridin derivati kot inhibitorji mehkih kamnov
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
WO2014145205A2 (fr) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Procédés et compositions de modulateurs de la transcription de p27kip1
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
KR20150133767A (ko) 2013-03-15 2015-11-30 온코디자인 에스.에이. 거대고리 염-유도성 키나아제 억제제
KR101548803B1 (ko) * 2013-09-09 2015-09-01 경북대학교병원 ３­（６­（４­（트리플루오로메톡시）페닐아미노）피리미딘­４­일）벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
EP3043803B1 (fr) 2013-09-11 2022-04-27 Emory University Compositions à base de nucléotide et de nucléoside et leur utilisations
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
CN103588758A (zh) * 2013-11-04 2014-02-19 南京大学 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
CA3178867A1 (fr) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Composes hydrazinyl-pyrrolo et procedes de production d'un conjugue
KR101602203B1 (ko) * 2014-03-11 2016-03-11 경북대학교병원 N­（2­하이드록시에틸）­3­（6­（4­（트리플루오로메톡시）페닐아미노）피리미딘-4-일）벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
WO2015150337A1 (fr) 2014-04-01 2015-10-08 Amakem Nv Inhibiteurs de la lim kinase
AU2015239108A1 (en) 2014-04-01 2016-10-20 Institut Jules Bordet New strategies for treating melanoma
WO2015161283A1 (fr) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques à utiliser dans des traitements de la prolifération de cellules anormales rb-positives, épargnant les cellules souches et les cellules progénitrices hématopoïétiques (hspc)
AU2015256266B2 (en) 2014-05-05 2019-01-17 Emory University BH4 antagonists and methods related thereto
US10450293B2 (en) 2014-05-16 2019-10-22 Emory University Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto
WO2016003450A1 (fr) 2014-07-01 2016-01-07 The Regents Of The University Of California Inhibiteurs de pkc-epsilon
EP3166955B1 (fr) 2014-07-08 2018-05-02 Universiteit Gent Analogues d'hamamélitannine et leurs utilisations
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
MX376087B (es) 2014-09-17 2025-03-07 Oncodesign Prec Medicine Opm Inhibidores macrocíclicos de cinasa rip2.
BR112017005299A2 (pt) 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
WO2016083490A1 (fr) 2014-11-27 2016-06-02 Remynd Nv Composés pour le traitement de maladies associées à la substance amyloïde
SG10202013032YA (en) 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016146651A1 (fr) 2015-03-16 2016-09-22 Oncodesign Sa Inhibiteurs macrocycliques de récepteur kinase de type activine
EP3288637B1 (fr) 2015-04-28 2022-09-14 NewSouth Innovations Pty Limited Ciblage de nad+ pour traiter la déficience cognitive, les neuropathies et l'inactivité induites par la chimiothérapie et la radiothérapie
WO2016179108A1 (fr) 2015-05-01 2016-11-10 Georgia State University Research Foundation Dérivés benzhydrol pour la prise en charge d'états associés à des facteurs inductibles par l'hypoxie
WO2016196297A1 (fr) 2015-05-29 2016-12-08 Emory University 2-amino-n'-benzylidène-acétohydrazides et dérivés pour la prise en charge de maladies médiées par la protéine cftr
CN108137595B (zh) * 2015-06-18 2021-04-20 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
ES2908470T3 (es) 2015-11-09 2022-04-29 Scherer Technologies Llc R P Conjugados de anticuerpo anti-CD22-maitansina y métodos de uso de los mismos
PT3423113T (pt) 2016-02-29 2020-12-10 Oncodesign Sa Inibidor de egfr macrocíclico radiomarcado
WO2017157882A1 (fr) 2016-03-14 2017-09-21 Université Catholique de Louvain Inhibiteurs de la voie de biosynthèse de la sérine
WO2017161253A1 (fr) * 2016-03-18 2017-09-21 Tufts Medical Center Compositions et méthodes de traitement et de prévention de troubles métaboliques
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2019516715A (ja) 2016-05-19 2019-06-20 ユニバーシタット アントウェルペン Ｐａｒ関連疾患の予防および／または治療における使用のためのビス（アセトアミドフェニル）グアニジノフェニルエチルホスホネート
BE1023757B1 (nl) 2016-06-30 2017-07-12 Yun NV Bewaring van micro-organismen
WO2018065387A1 (fr) 2016-10-04 2018-04-12 Universiteit Gent Nouveaux analogues du hamamélitannin et leurs utilisations
US20190256573A1 (en) 2016-10-14 2019-08-22 Emory University Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
WO2018081442A1 (fr) 2016-10-26 2018-05-03 Emory University Complexes de polyoxométallate et leurs utilisations dans la prise en charge du cancer
EP3544952B1 (fr) 2016-11-24 2024-11-06 Universiteit Antwerpen Benzotropolones halogenes comme inhibitors de atg4b
EP3554533B1 (fr) 2016-12-13 2021-06-09 Emory University Polypeptides pour la prise en charge d'infections virales
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018138358A1 (fr) 2017-01-30 2018-08-02 Université de Liège Inhibiteurs de perk et d'ire-1a contre des troubles neurodéveloppementaux
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
US10981896B2 (en) 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN106977508A (zh) * 2017-05-05 2017-07-25 遵义医学院 具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法
EP3634407A1 (fr) 2017-05-11 2020-04-15 Remynd N.V. Inhibiteurs de pde6delta destinés à être utilisés dans la prévention et/ou le traitement de l'épilepsie et/ou de troubles neurodégénératifs
EA201992397A1 (ru) 2017-05-11 2020-03-16 Реминд Н.В. Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
EP4455146A3 (fr) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Formes morphiques de git38 et leurs procédés de fabrication
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
EP3773562A1 (fr) 2018-04-05 2021-02-17 Universiteit Hasselt Inhibiteurs sélectifs de pde4d contre des maladies démyélinisantes
US12090124B2 (en) 2018-06-29 2024-09-17 Rejuvenate Biomed Nv Pharmaceutical combination for use in age- related and/or degenerative diseases
EP3833343B1 (fr) 2018-08-07 2024-02-21 Emory University Dérivés hétérocycliques de flavone, compositions et procédés associés
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
WO2020070331A1 (fr) * 2018-10-05 2020-04-09 Ichnos Sciences S.A. Composés d'indolinone servant d'inhibiteurs de map4k1
US12240829B2 (en) 2019-03-20 2025-03-04 Emory University Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto
ES2966719T3 (es) 2019-05-14 2024-04-23 Suzhou Four Health Pharmaceuticals Co Ltd Derivados de quinazolina-2,4-diona como inhibidores de PARP
AU2020284308B2 (en) 2019-05-24 2026-02-05 Emory University Asparagine endopeptidase (AEP) inhibitors, compositions, and uses related thereto
EP4003996B1 (fr) * 2019-07-22 2025-05-21 Radius Pharmaceuticals, Inc. Composés modulant les récepteurs des oestrogènes
BR112022016733A2 (pt) 2020-02-24 2022-10-11 Univ Leuven Kath Compostos antivirais de pirrolpiridina e imidazopiridina
GB202003240D0 (en) 2020-03-05 2020-04-22 Ecosynth Nv Antiviral treatment
EP4121121A4 (fr) 2020-03-16 2024-09-25 Emory University Traceurs radionucléides de l'acide 1-amino-3,4-difluorocyclopentane-1-carboxylique, leurs dérivés et leurs utilisations
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US20240350492A1 (en) 2020-07-10 2024-10-24 Ting Therapeutics Llc Methods for the Prevention and Treatment of Hearing Loss
WO2022157381A1 (fr) 2021-01-25 2022-07-28 Universiteit Hasselt Phlorétine destinée à être utilisée dans le traitement de maladies neurodégénératives et démyélinisantes
WO2022191501A1 (fr) * 2021-03-12 2022-09-15 주식회사 온코크로스 Composition destinée au traitement de cancer résistant à des agents anticancéreux
JP2024529430A (ja) 2021-07-26 2024-08-06 セルキュイティー インコーポレイテッド がんの処置における使用のための１－（４－｛［４－（ジメチルアミノ）ピペリジン－１－イル］カルボニル｝フェニル）－３－［４－（４，６－ジモルホリン－４－イル－１，３，５－トリアジン－２－イル）フェニル］尿素（ゲダトリシブ）およびその組合せ
MX2024001155A (es) 2021-07-30 2024-07-01 Confo Therapeutics N V Compuestos para el tratamiento del dolor, en particular el dolor neuropatico, y/u otras enfermedades o trastornos que se asocian con at2r y/o se?alizacion mediada por at2r.
WO2023021132A1 (fr) 2021-08-18 2023-02-23 Katholieke Universiteit Leuven Analogues de ribonucléoside 7-déazapurine 6-substitués et 6,7-disubstitués
WO2023046900A1 (fr) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Analogues de ribonucléosides dirigés contre le sars-cov-2
WO2023105283A1 (fr) 2021-12-08 2023-06-15 Fundacio Privada Institut De Recerca De La Sida - Caixa Inhibiteurs nucléosidiques de la transcriptase inverse destinés à être utilisés dans le traitement du syndrome de down et de la maladie d'alzheimer
WO2023111683A1 (fr) 2021-12-16 2023-06-22 Ascletis Bioscience Co., Ltd. Dérivés de n4-hydroxycytidine et leur utilisation comme agent antiviral
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
WO2023139402A1 (fr) 2022-01-18 2023-07-27 Ascletis Bioscience Co., Ltd. Inhibiteurs de cystéine protéases et leurs procédés d'utilisation
US11760722B2 (en) 2022-01-18 2023-09-19 Ascletis Bioscience Co., Ltd. Inhibitors of cysteine proteases and methods of use thereof
WO2023180567A1 (fr) 2022-03-24 2023-09-28 Fundacion Privada Institut De Recerca De La Sida-Caixa Cyclodextrines destinées à être utilisées dans une thérapie contre une infection à coronavirus
WO2023241799A1 (fr) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols destinés à être utilisés dans le traitement d'infections rétrovirales
WO2024009120A1 (fr) 2022-07-08 2024-01-11 Ascletis Bioscience Co., Ltd. Dérivés de triazine et leurs procédés d'utilisation
CN117700397A (zh) * 2022-11-02 2024-03-15 徐诺药业(南京)有限公司 2-氧代吲哚啉类衍生物及其制备方法和应用
CN115504968B (zh) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
WO2024193451A1 (fr) 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Dérivés de triazine, leur procédé de fabrication et leur procédé d'utilisation
WO2025104221A1 (fr) 2023-11-15 2025-05-22 Université Libre de Bruxelles Utilisations d'inhibiteurs kappa du récepteur de la protéine tyrosine phosphatase
WO2025155711A1 (fr) * 2024-01-17 2025-07-24 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs de lrrk2 et compositions et utilisations associées
WO2026013165A1 (fr) 2024-07-10 2026-01-15 Université Libre de Bruxelles Association d'un inhibiteur de ship2 et d'un inhibiteur de plk1 destinée à être utilisée dans le traitement du cancer
WO2026024674A1 (fr) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Méthodes de traitement de cancers associés à skp2
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2447940A1 (fr) 1979-02-05 1980-08-29 Ato Chimie Nouveaux (co)polycarbonates resistant au feu contenant des fonctions diesters ou hemiesters alcalins d'acides phosphoniques
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
JP2877508B2 (ja) 1989-02-08 1999-03-31 アボツト・ラボラトリーズ ５―リポキシゲナーゼ阻止剤としての４―ヒドロキシチアゾール
WO1991009598A1 (fr) 1990-01-05 1991-07-11 Pfizer Inc. Derives de l'azaoxindole
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5164404A (en) 1991-03-15 1992-11-17 Neurosearch A/S Hydrazone derivatives and their use
WO1992020796A2 (fr) 1991-05-16 1992-11-26 Cold Spring Harbor Laboratory Cyclines du type d et leurs utilisations
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
JPH07502164A (ja) 1991-09-20 1995-03-09 フレッド ハッチンソン キャンサー リサーチ センター ヒトサイクリンｅ
US5294538A (en) 1991-11-18 1994-03-15 Cold Spring Harbor Labs. Method of screening for antimitotic compounds using the CDC25 tyrosine phosphatase
US5770423A (en) 1991-11-18 1998-06-23 Cold Spring Harbor Laboratory Nucleic acids encoding cdc25 A and cdc25 B proteins and method of making cdc25 A and cdc25 B proteins
US5441880A (en) 1991-11-18 1995-08-15 Cold Spring Harbor Laboratory Human cdc25 genes, encoded products and uses thereof
WO1993024514A1 (fr) 1992-05-26 1993-12-09 Mitotix Cycline de type d et utilisations correspondantes
WO1994023029A1 (fr) 1993-03-31 1994-10-13 Monash University Sequence de nucleotides codant une proteine chromosomique, proteines chromosomiques associees et leurs utilisations
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
CA2235810C (fr) 1994-10-24 2010-02-09 Baylor College Of Medicine Inhibiteurs de synthese d'adn produits dans des cellules senescentes
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997025986A1 (fr) 1996-01-17 1997-07-24 Taiho Pharmaceutical Co., Ltd. Inhibiteurs d'epaississement de l'intima
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
EP0788890A1 (fr) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Colorants et éléments donneur de colorant pour l'enregistrement par transfert thermique de colorant
CZ293628B6 (cs) 1996-03-29 2004-06-16 Pfizer Inc. Benzyl(iden)laktamové deriváty a jejich použití a farmaceutické kompozice na jejich bázi
WO1998007835A2 (fr) 1996-08-21 1998-02-26 Sugen, Inc. Structures cristallines d'une proteine tyrosine kinase
AU4155697A (en) 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
JP2002511852A (ja) * 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6319918B1 (en) 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6620818B1 (en) * 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy

Also Published As

Publication number Publication date
AR015432A1 (es) 2001-05-02
US6369086B1 (en) 2002-04-09
DE69824014D1 (en) 2004-06-24
PE107699A1 (es) 1999-11-24
JP2001517652A (ja) 2001-10-09
PL338991A1 (en) 2000-12-04
DE69824014T2 (de) 2005-05-12
ES2221211T3 (es) 2004-12-16
GB9718913D0 (en) 1997-11-12
ZA988078B (en) 2000-03-22
ATE267170T1 (de) 2004-06-15
TW520358B (en) 2003-02-11
US6387919B1 (en) 2002-05-14
CA2302572A1 (fr) 1999-04-01
AU747506B2 (en) 2002-05-16
US20030004351A1 (en) 2003-01-02
US6541503B2 (en) 2003-04-01
HUP0004490A2 (en) 2001-03-28
MA26542A1 (fr) 2004-12-20
KR20010023695A (ko) 2001-03-26
TR200001174T2 (tr) 2000-08-21
HUP0004490A3 (en) 2002-10-28
EP1009738B1 (fr) 2004-05-19
WO1999015500A1 (fr) 1999-04-01
US7105529B2 (en) 2006-09-12
CO4960633A1 (es) 2000-09-25
CN1278794A (zh) 2001-01-03
BR9812048A (pt) 2000-09-26
EP1009738A1 (fr) 2000-06-21
AU9740798A (en) 1999-04-12
US20030069430A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
EE200000117A (et) Asendatud oksindooli derivaadid kui proteiini türosiini kinaasi ja proteiini seriini/treoniini kinaasi inhibiitorid
EE200000411A (et) Bitsüklilised heteroaromaatsed ühendid kui valgu türosiini kinaasi inhibiitorid
FI950859A7 (fi) Arylideeni- ja heteroarylideeni-oksindolijohdannaiset tyrosiinikinaasi-inhibiittoreina
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
EE9900527A (et) Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid
DK1117659T3 (da) Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
NO20000487D0 (no) Substituerte quinazolinderivater og anvendelse derav som tyrosin kinase inhibitorer
AU3505000A (en) 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
FI972492L (fi) Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
NO20020467L (no) Purinderivatinhibitorer av tyrosinproteinkinase syk
EE200000289A (et) Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
HUP0102101A3 (en) Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
NO990124D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
NO990123D0 (no) Bicykliske heteroaromatiske forbindelser som protein-tyrosin-kinase-inhibitorer
EE200000706A (et) Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
ATE430149T1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
ATE214381T1 (de) Thiazole derivate als protein kinase c inhibitoren
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
DK1171440T3 (da) Substituerede 3-cyano-[1,7]-, [1,5]- og [1,8]-naphthyridininhibitorer af tyrosinkinaser
FI955661L (fi) Substituoidut beta-aryyli- ja beta-heteroaryyli-alfa-syanoakryyliamidijohdannaiset tyrosiinikinaasi-inhibiittoreina
ATE209626T1 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
HK1025569A (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
GB9425409D0 (en) Inhibitors of protein tyrosine kinases